We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Quantum Phar. | LSE:QP. | London | Ordinary Share | GB00BRTL8Q42 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 84.2374 | 84.00 | 84.75 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
13/5/2016 10:02 | Huge trade..Leg and Gen buying again? | gymratt | |
12/5/2016 12:16 | Confirmation of latest forecasts from N+1 Singer: this year : 6.5p EPS, 1.8p divi next year : 7.6p EPS, 2.3P divi | rivaldo | |
10/5/2016 12:59 | I bought in at £1.30 and have been dismayed with the fall. Today is good news and I hope they get the new products launched soon | werewolfie | |
10/5/2016 10:04 | For now all the operating cash flow goes straight out again in R&D costs. I suspect Mr Market remains sceptical until all this R&D spend bears fruit. | eezymunny | |
10/5/2016 08:02 | 6 months to pay the dividend! really? | r ball | |
10/5/2016 07:56 | The outlook looks strong and an upbeat announcement generally,it seems to me. | hazl | |
10/5/2016 07:55 | £6m capitalised development costs? | spooky | |
10/5/2016 07:46 | Results look OK to me at first glance. In particular, the 7.4p adjusted EPS (note 4) is well ahead of 6.1p expectations. The 1.5p divi is perfectly in line. A strong Q1'16 performance is good to hear, though there's an H2 weighting. The confidence for this year is also reassuring, along with the pipeline of products due to launch this financial year being "currently on track". QP. is certainly pretty decent value prima facie given forecasts of 6.5p EPS, with a 1.8p divi - perhaps this update will be enough to initiate a return of confidence. | rivaldo | |
10/5/2016 07:36 | sorry r ball is this a postive update | ali47fish | |
10/5/2016 07:29 | Well these's your problems:- NuPharm Goodwill right offs Too many management distractions (relocating to Basingstoke, MHRA NuPharm regulatory impact, new divisional MD and Group FD). A lot going on for such a small company. | r ball | |
06/5/2016 18:20 | I think it would go as for QP67% of share promoter holding Total number of share only 125 m20 products in pipeline | p_dharmendra | |
06/5/2016 17:21 | So time to remortgage the house, max out the credit card etc. Unlikely. I would be happy with 64p and 70p by June. | r ball | |
05/5/2016 21:51 | Next Tuesday QP Final results It will be turned round result SP will touch 100 end of next week And 125 at end of May | p_dharmendra | |
03/5/2016 08:37 | Yep, good to see. | rivaldo | |
03/5/2016 07:09 | legal and gen are adding | ali47fish | |
28/4/2016 14:25 | Rivaldo, the PE is rather low @8.9. I think this will do good in time. Patience is required. ATB to all holders. | callmebwana | |
28/4/2016 13:53 | An article in last week's Shares Mag had a whole page on QP., concluding that "rewards are potentially high if it doesn't disappoint the market again". It has "around 70 candidates in its niche product pipeline", and "plans to launch a significant number of products in the next 12 months". It's trading at 8.9 times prospective earnings "based on N+1 Singer's 6.5p earnings per share" forecast to 31/1/17. | rivaldo | |
19/4/2016 08:52 | Does feel like the worm might be finally turning - need to break and hold 70p now | davr0s | |
19/4/2016 08:36 | The recent news would appear to indicate that the delays in the Colonis product pipeline are not as severe as first thought. Or am I being overly optimistic? | busterdog2 | |
19/4/2016 08:02 | Copied from other QP. Thread. Unsure which one is regularly used. Further positive news this morning...7th product release from the Niche stable which completes QP's Vitamin D range & allows the company to offer 4 different strengths of licensed products. As I understand it addresses treatment for acute deficiency & maintenance for a £0.5 - £1m market. Regards, GHF | glasshalfull | |
19/4/2016 08:01 | Further positive news this morning...7th product release from the Niche stable which completes QP's Vitamin D range & allows the company to offer 4 different strengths of licensed products. As I understand it addresses treatment for acute deficiency & maintenance and market between £0.5 - £1m. Regards, GHF | glasshalfull | |
18/4/2016 15:45 | best its looked for a while imo | hazl | |
18/4/2016 13:46 | Good to see QP. continuing its (very) mini-revival today, and on decent volumes too. Results are on 10th May, and the latest forecasts are for historic 6.1p EPS and 6.5p EPS for this year, with 1.5p and 1.8p dividends respectively. The historic forecast should be pretty spot on given the trading statement, and this year's looks nicely conservative, so hopefully there's room for upside with more news flow. With no more surprises and stable markets it's possible to see QP. back at 80p post-results and back to 100p+ with decent news. | rivaldo |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions